<DOC>
	<DOCNO>NCT02642406</DOCNO>
	<brief_summary>Despite treatment improvement breast cancer , large number patient still progress metastatic stage . Metastatic breast cancer patient extremely unfavorable prognosis . Not efficacy , also quality life focus plan therapy therapy sequence metastatic breast cancer patient . Therapy option include anti-hormonal Therapy , antibody therapy , target therapy chemotherapy . One effective chemotherapy adjuadjuvant metastatic setting paclitaxel . However drug handle side effect compromise patient quality life impact pharmacokinetics drug . In metastatic breast cancer patient increase therapy efficacy reduction side effect frequency consider advancement therapy . One advancements development cremophor free albumin bound paclitaxel , nab-Paclitaxel ( Abraxane ) , think well efficacy reduced toxicity profile . Nab-Paclitaxel approve treatment metastatic breast cancer failure first-line therapy antracyclines indicate . The SERAPHINA study aim investigate use nab-Paclitaxel daily routine frequency perception side effect . As non-interventional study , SERAPHINA Study assess patient characteristic describe patient cohort , nab-Paclitaxel give . This include age distribution , molecular epidemiological characteristic characteristic document patient .</brief_summary>
	<brief_title>Therapy Management With Nab-Paclitaxel Daily Routine</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients metastatic breast cancer therapy nabpaclitaxel indicate treat physician Treatment nabPaclitaxel must either start yet , first application nabPaclitaxel prior 21 day study entry Female patient , age â‰¥18 year Invasive breast cancer ( irrespective status BC , e.g . TNM , receptor status etc . ) Metastatic locally advance , inoperable disease proven clinical measure ( i.e . standard image ) Patients schedule nabPaclitaxel treatment daily routine screening Patients , able willing sign inform consent form Patient currently enrol , enroll interventional clinical study investigational therapeutic procedure perform investigational therapy administer participate study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>